Spotlight Poster Discussion 2 – Wednesday, December 9, 2020: 5:15 pm – 6:30 pm
   
  Refining Targeted Therapy in HR+ Disease
PD2-01 High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE
Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, Song C, Molthrop D, Vuky J, Yamashita T, Jaliffe GG, Gumus M, Headley D, Wei1 R, Barriga S, Munoz M, Method M, Andre V, Kreipe H, O'Shaughnessy J. Breast Center, Ludwig-Maximilians-Universität München (LMU), Munich, Germany; Royal Marsden NHS Foundation Trust, London, United Kingdom; University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Kyoto University Hospital, Kyoto, Japan; University of Pittsburgh, Pittsburgh, PA; Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China; Fujian Medical University Union Hospital, Department of Breast Surgery, Fujian, China; Florida Cancer Specialists, Orlando, FL; OHSU Knight Cancer Institute, Portland, OR; Kanagawa Cancer Center, Kanagawa, Japan; Grupo Médico CAMINO S.C., Mexico City, Mexico; Istanbul Medeniyet University, School of Medicine, Dept of Medical Oncology, Istanbul, Turkey; Eli Lilly and Company, Indianapolis, IN; Medizinische Hochschule Hannover, Hannover, Germany; Texas Oncology, Dallas, TX.
PD2-03 Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer
Mayer EL, Fesl C, Dueck A, Gnant M, DeMichele A, on behalf of the PALLAS study team. Dana-Farber Cancer Institute, Boston, MA; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Mayo Clinic Scottsdale, Scottsdale, AZ; Medical University of Vienna, Vienna, Austria; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
PD2-04 Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im Y-H, Kümmel S, El-Saghir N, Liu M-C, Kaur S, Gasch C, Wang C, Wang Y, Chakravartty A, Lu Y-S. The University of Texas MD Anderson Cancer Center, Houston, TX; Seoul National University College of Medicine, Seoul, Republic of Korea; Unità di Ricerca in Senologia Medica – Istituto Europeo di Oncologia, Milan, Italy; Hospital de Caridade de Ijuí, CACON, Ijuí, Brazil; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Organisation for Oncology and Translational Research, Hong Kong, China; Severance Hospital of Yonsei University Health System, Seoul, Republic of Korea; Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Institut Català d’Oncologia, Hospital Moisès Broggi, Barcelona, Spain; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; HCG Curie Centre of Oncology and Kidwai Memorial Institute of Oncology, Bangalore, India; University of Ottawa, Ottawa, ON, Canada; Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Breast Unit, Kliniken Essen-Mitte, Essen, Germany; American University of Beirut Medical Center, Beirut, Lebanon; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; Novartis Healthcare Pvt Ltd, Hyderabad, India; Novartis Ireland Limited, Dublin, Ireland; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Taiwan University Hospital, Taipei, Taiwan.
PD2-05 Randomized phaseII trial to evaluate alisertib alone or combined with fulvestrant for advanced, endocrine-resistant breast cancer (TBCRC 041)
Haddad T, D'Assoro A, Suman V, Carter J, McMenomy B, Mayer E, Karuturi M, Morikawa A, Marcom P, Isaacs C, Young Oh S, Clark A, Mayer I, Keyomarsi K, Leon-Ferre R, Giridhar K, O'Sullivan C, Peethambaram P, Hobday T, Liu M, Ingle J, Goetz M. Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute-Harvard Medical School, Boston, MA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI; Duke Cancer Institute, Durham, NC; Georgetown University, Washington, DC; Montefiore Medical Center, New York, NY; University of Pennsylvania, Philadelphia, PA; Vanderbilt University Medical Center, Nashville, TN.
PD2-06 Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study
Ciruelos EM, Loibl S, Mayer IA, Campone M, Rugo HS, Arnedos M, Iwata H, Conte PF, André F, Reising A, Ma1 C, Miller M, Babbar N, Juric D. University Hospital 12 de Octubre, Madrid, Spain; German Breast Group, Neu-Isenburg, Germany; Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TX; Institut de Cancérologie de l’Ouest, St. Herblain, France; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institut Gustave Roussy, Villejuif, France; Aichi Cancer Center Hospital, Aichi, Japan; Istituto Oncologico Veneto, University of Padua, Padua, Italy; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharmaceuticals Corporation, Cambridge, MA; Department of Oncology/Hematology, Gillette Center for Women's Cancer, Massachusetts General Hospital Cancer Center, Boston, MA.
PD2-07 Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
Rugo HS, Lerebours F, Juric D, Turner N, Chia S, Drullinsky P, Prat A, Villanueva Vázquez R, Akdere M, Arce C, Shen Y-M, Ciruelos E. University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institut Curie-Saint Cloud, Saint Cloud, France; Massachusetts General Hospital Cancer Center, Boston, MA; The Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Memorial Sloan Kettering Cancer Center, New York, NY; Hospital Clinic of Barcelona, Barcelona, Spain; Institut Català d’Oncologia - Hospital Duran i Reynals - L’Hospitalet, Barcelona, Spain; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharmaceuticals Corporation, Munich, Germany; Hospital Universitario 12 de Octubre, Madrid, Spain.
PD2-08 Endocrine therapy non-persistence and recurrence in young women with early stage breast cancer
Rosenberg SM, Zheng Y, Poorvu P, Ruddy K, Gaither R, Tamimi R, Schapira L, Peppercorn J, Come S, Borges V, Partridge A. Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Weill Cornell Medicine, New York, NY; Stanford Cancer Institute, Stanford, CA; Massachusetts General Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO.
PD2-09 The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)
Goetz MP, Fleming GF, Kuffel M, Hawse JR, Black JL, Weinshilboum R, Ingle JN, dell’Orto P, Biasi O, Kammler R, Loi S, Colleoni M, Viale G, Francis PA, Regan MM. Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; European Institute of Oncology IRCCS, Milan, Italy; IBCSG Coordinating Center, Bern, Switzerland; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia; Dana-Farber Cancer Institute, Boston, MA.
PD2-10 Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): an ALTERNATE trial analysis (Alliance A011106)
Ellis MJ, Suman V, Leitch AM, Sanati S, Vij K, Unzeitig GW, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Maluf H, Dowsett M, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Dockter T, Zujewski JA, Weiss A, Hudis C, Winer EP, Hunt K, Partridge AH, Ma CX, Carey LA. Baylor College of Medicine, St. Louis, MO; Alliance Statistics and Data Center, Rochester, MN; University of Texas Southwestern Medical Center, Dallas, TX; Cedars-Sinai Medical Center, Los Angelos, CA; Washington University School of Medicine, St. Louis, MO; Doctor's Hospital of Laredo, Laredo, TX; University of Chicago, Chicago, IL; Saint Elizabeth Medical Center South, Edgewood, KY; MD Anderson Cancer Center, Houston, TX; The Royal Marsden, London, United Kingdom; Mount Sinai Hospital, New York, NY; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Mayo Clinic, Rochester, MN; Presbyterian Kaseman Hospital, Albuquerque, NM; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; University of North Carolina, Chapel Hill, NC.
PD2-11 Breast cancer index is a molecular signature of endocrine responsiveness that determines extended endocrine benefit independent of prognostic risk
Liefers G-J, Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Van De Velde CJH, Schnabel CA. Leiden University Medical Center, Leiden, Netherlands; Biotheranostics, Inc., San Diego, CA.